Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dp001. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR known ✓ | P11473 | 6/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dp001 SCHEMBL12961887 | 1.00 | VDR (0.81) | VDR | |
| Dp001 SCHEMBL19988220 | 1.00 | VDR (0.81) | VDR | |
| Dp001 SCHEMBL29645040 | 1.00 | VDR (0.81) | VDR | |
| Dp001 SCHEMBL15371114 | 1.00 | VDR (0.81) | VDR | |
| Dp001 SCHEMBL15371106 | 1.00 | VDR (0.81) | VDR | |
| Dp001 SCHEMBL18470321 | 1.00 | VDR (0.81) | VDR | |
| Dp001 SCHEMBL12932256 | 1.00 | VDR (0.81) | VDR | |
| Dp001 SCHEMBL10307542 | 1.00 | VDR (0.81) | VDR | |
| Dp001 SCHEMBL21206294 | 1.00 | VDR (0.81) | VDR | |
| Dp001 SCHEMBL12332637 | 1.00 | VDR (0.81) | VDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3763419-A1 | CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES | Anji Pharma (US) LLC (US) | 2021-01-13 | — | — | EP | disclosed |
| US-10610500-B2 | Chemosensory receptor ligand-based therapies | ANJI PHARMA (US) LLC (US) | 2020-04-07 | — | — | US | disclosed |
| US-10369161-B2 | Use of 2-methylene-19-NOR-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat primary hyperparathyroidism | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2019-08-06 | — | — | US | disclosed |
| US-20190038576-A1 | Chemosensory Receptor Ligand-Based Therapies | ANJI PHARMACEUTICALS INC. | 2019-02-07 | — | — | US | disclosed |
| US-9962344-B2 | Chemosensory receptor ligand-based therapies | ELCELYX THERAPEUTICS, INC. (US) | 2018-05-08 | — | — | US | disclosed |
| US-9962344-B2 | Chemosensory receptor ligand-based therapies | ELCELYX THERAPEUTICS, INC. (US) | 2018-05-08 | — | — | US | disclosed |
| US-20180055856-A1 | COMBINATION OF LOW DOSE 2-METHYLENE-19-NOR-(20S)-1ALPHA, 25-DIHYDROXYVITAMIN D3 AND CALCIMIMETICS TO TREAT SECONDARY HYPERPARATHYROIDISM | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2018-03-01 | — | — | US | disclosed |
| US-20180055856-A1 | COMBINATION OF LOW DOSE 2-METHYLENE-19-NOR-(20S)-1ALPHA, 25-DIHYDROXYVITAMIN D3 AND CALCIMIMETICS TO TREAT SECONDARY HYPERPARATHYROIDISM | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2018-03-01 | — | — | US | disclosed |
| US-9814736-B2 | Use of 2-methylene-19-nor-(20S)-1α,25-dihydroxyvitamin D3 and calcimimetics to treat secondary hyperparathyroidism | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2017-11-14 | — | — | US | disclosed |
| US-9814736-B2 | Use of 2-methylene-19-nor-(20S)-1α,25-dihydroxyvitamin D3 and calcimimetics to treat secondary hyperparathyroidism | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2017-11-14 | — | — | US | disclosed |
| US-7718636-B2 | Use of 2-methylene-19-nor-20(S)-1alpha,25dihydroxy vitamin d3 to inhibit mammary tumor | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2010-05-18 | — | — | US | disclosed |
| US-20090143342-A1 | 26,27-homologated-20-EPI-2-alkylidene-19-nor-vitamin D compounds | WISCONSIN ALUMNI RESEARCH FOUNDATION OF MADISON | 2009-06-04 | — | — | US | disclosed |
| US-20090143342-A1 | 26,27-homologated-20-EPI-2-alkylidene-19-nor-vitamin D compounds | WISCONSIN ALUMNI RESEARCH FOUNDATION OF MADISON | 2009-06-04 | — | — | US | disclosed |
| EP-1494680-B1 | USE OF CARBON-2-MODIFIED-VITAMIN D ANALOGS TO INDUCE THE FORMATION OF NEW BONE | WISCONSIN ALUMNI RES FOUND (US) | 2008-09-03 | — | — | EP | disclosed |
| EP-1268416-B1 | 2-ALKYLIDENE-19-NOR-VITAMIN D COMPOUNDS AND THEIR THERAPEUTIC USES | WISCONSIN ALUMNI RES FOUND (US) | 2007-09-26 | — | — | EP | disclosed |
| US-7214671-B2 | Administering -methylene-19-nor-20(S)-1 alpha ,25-dihydroxyvitamin D3 for prophylaxis of osteoporosis | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2007-05-08 | — | — | US | disclosed |
| US-7214670-B2 | Use of 2-methylene-19-nor-20(S)-1α,25-dihydroxyvitamin D3 to increase the life expectancy of human beings | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2007-05-08 | — | — | US | disclosed |
| US-7214670-B2 | Use of 2-methylene-19-nor-20(S)-1α,25-dihydroxyvitamin D3 to increase the life expectancy of human beings | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2007-05-08 | — | — | US | disclosed |
| US-7214671-B2 | Administering -methylene-19-nor-20(S)-1 alpha ,25-dihydroxyvitamin D3 for prophylaxis of osteoporosis | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2007-05-08 | — | — | US | disclosed |
| WO-2005027913-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS COMPRISING COMBINATIONS OF 2-ALKYLIDENE-19-NOR-VITAMIN D DERIVATIVES AND A GROWTH HORMONE SECRETAGOGUE | PFIZER PRODUCTS INC. (US) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180055856-A1 | COMBINATION OF LOW DOSE 2-METHYLENE-19-NOR-(20S)-1ALPHA, 25-DIHYDROXYVITAMIN D3 AND CALCIMIMETICS TO TREAT SECONDARY HYPERPARATHYROIDISM | PTH1R, CYP24A1, VDR | VDR 3/4885 |
| US-20090143342-A1 | 26,27-homologated-20-EPI-2-alkylidene-19-nor-vitamin D compounds | VDR, CYP24A1, CYP2R1 | VDR 1/4885 |
| US-10610500-B2 | Chemosensory receptor ligand-based therapies | TAS1R2, TAS2R1, GPR119 | VDR 371/4885 |
| US-20190038576-A1 | Chemosensory Receptor Ligand-Based Therapies | TAS1R2, TAS2R1, GPR119 | VDR 371/4885 |
| US-10369161-B2 | Use of 2-methylene-19-NOR-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat primary hyperparathyroidism | CYP24A1, PTH1R, CYP2R1 | VDR 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.